RIDO Stock Investment TV

.

3 Stocks to Get on Your Watchlist


By Sean Williams
April 4, 2012 
Article from The Motley Fool

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up on my favorite sectors and what's really moving the market. Even worse, without my watchlist, I'd be lost when it came time to choose what stock I'm buying or shorting next.

Today is "Watchlist Wednesday," so I'm discussing three companies that have crossed my radar in the past week and at what point I may consider taking action on these calls with my own money. Keep in mind, these aren't concrete buy or sell recommendations, nor do I guarantee I'll take action on the companies being discussed weekly. What I can promise is that you can follow my real-life transactions through my profile, and that I, like everyone else here at The Motley Fool, will continue to hold the integrity of our disclosure policy in the highest regard.

Autodesk (Nasdaq: ADSK  ) 

I may not talk about it often enough, but Autodesk is one of the most consistent growth stories in software. The company, like a growing number of software names, is capitalizing on businesses moving into the cloud. Its AutoCAD software, which allows users from the manufacturing sector to draft and design projects, is a driving force behind the company's growth. According to Autodesk's CEO, Carl Bass, more than 300,000 documents per week are being uploaded to its mobile device program, AutoCAD WS, thanks in part to a surge in sales from Apple's (Nasdaq: AAPL  ) iPad.

This is one major key to Autodesk's success: attacking the mobile software space in addition to standard PCs and laptops. Not many software providers can say they've been profitable in each of the past 10 years, but Autodesk can. With a debt-free balance sheet, $1.4 billion in cash and a five-year projected growth rate of nearly 17%, there doesn't seem to be any reason not to be bullish on Autodesk.

Corning (NYSE: GLW  ) 

I'm not exactly sure when this happened, but Corning just became a value play. Corning is the company behind the extremely shatter-resistant Gorilla Glass, as well as myriad other products in the fiber optic and life sciences sectors. If you recall, mobile, fiber optics and life sciences are three of my favorite sectors at the moment, granting Corning my trifecta of approval.

As smartphones begin to flood the market, their average selling price should drop, which will facilitate even more sales. More smartphone sales very simply mean more sales for Corning, since its fiber optic products and its protective glass are becoming essential tools to keeping Apple's iPhone 4S the most dominant phone on the market. Corning is loaded with $3.4 billion in net cash, is trading right at book value, and is priced at just nine times forward earnings. I'm not sure this is going to get any cheaper, so it looks like a genuine bargain here.

Conn's (Nasdaq: CONN  ) 

The recent rally in Conn's makes about as much sense as a $3 bill to me. The company sells consumer appliances, electronics, lawn products, garden products, and mattresses. Let's just quickly take a glance at how some of these sectors have performed.

In home electronics, Best Buy (NYSE: BBY  ) reported the need to close down 50 of its large stores in favor of opening 100 smaller, mobile-based stores. This is in response to terrible margins on televisions and the growing presence of online buyers. In lawn and garden, Trex, a provider of outdoor decking and railing products, reported a 32% drop in sales year over year based on its fourth-quarter results released in late February. As for mattresses, Sealy imploded in January after it lowered its full-year forecast.

This either means Conn's is just really that good, or emotions have gotten the better of investors here. As for me, I'm going to err on the side of the latter.

Foolish roundup

Is my bullishness or bearishness misplaced? Share your thoughts in the comments section below, and consider following my cue by using the links below to add these three companies to your free personalized watchlist to keep up on the latest news with each company.

Don't let your search for great stocks end here. Consider getting your copy of our latest special report: "The Motley Fool's Top Stock for 2012." This report details a company that our chief investment officer has described as the "Costco of Latin America," and it's yours for the low, low price of free -- so don't miss out!

The Steve Jobs Betrayal 
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. He's a total nerd when it comes to making lists. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of Apple, Corning, and Best Buy. Motley Fool newsletter services have recommended buying shares of Apple and Corning, as well as creating a bull call spread position on Apple. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that believes transparency comes first.

Article from The Motley Fool

US HOT STOCKS: Avon, Groupon, Global Payments, Express Scripts


April 2, 2012, 1:46 p.m. ET
Article from The Wall Street Journal

U.S. stocks traded higher Monday as the Dow Jones Industrial Average recently rose 69 points to 13281, the Standard & Poor's 500-stock index moved up 12 points to 1420, and the Nasdaq Composite gained 26 points to 3118. Among the companies whose shares are actively trading in the session are Avon Products Inc. (AVP), Groupon Inc. (GRPN) and Global Payments Inc. (GPN).

Fragrance maker Coty Inc. offered to acquire Avon Products ($22.53, +$3.17, +16.37%) in a cash deal that values the struggling door-to-door beauty-products seller at roughly $10 billion. Coty is offering $23.25 a share to Avon shareholders, a 20% premium to Friday's closing price. Avon immediately rejected the offer, saying it was opportunistic and substantially undervalues the company, adding it remains confident in its stand-alone prospects and is committed to its previously announced CEO search.

Groupon ($16.28, -$2.10, -11.43%) lowered its reported fourth-quarter results after the online daily-deals service discovered it had to set aside more money for customer refunds. Auditor Ernst & Young also discovered a "material weakness in its internal controls" for the year.

Global Payments ($45.96, -$1.54, -3.24%), the credit-card processor that reported a significant security breach Friday, said hackers stole account numbers and other key information from up to 1.5 million accounts in North America. The news, released Sunday night in a statement, came after the company received a fresh blow over the weekend when Visa Inc. (V, $119.76, +$1.76, +1.49%) yanked its seal of approval from the company. Shares continued to fall Monday, after ending down more than 9% on Friday. Separately, the payment-processing company said Monday that its fiscal third-quarter earnings rose 21% as its stronger-than-expected revenue improved margins and offset rising costs.

Keryx Biopharmaceuticals Inc. (KERX, $1.69, -$3.30, -66.16%) and Aeterna Zentaris Inc. (AEZS, $0.75, -$1.39, -65.01%) reported the combined use of perifosine and the chemotherapy-drug capecitabine as a treatment for refractory advanced colorectal cancer didn't meet a Phase 3 clinical trial's primary endpoint. The companies said the study of 468 patients at 65 U.S. sites found perifosine with capecitabine didn't improve the overall survival rate when compared with capecitabine alone.

Express Scripts Inc. (ESRX, $56.17, +$1.99, +3.67%) said it completed its $29.1 billion acquisition of Medco Health Solutions Inc. (MHS, $71.71, +$1.41, +2.01%) following the Federal Trade Commission's decision that the combination of the two largest pharmacy-benefits management companies in the U.S. wouldn't change the competitive landscape in the sector.


   Other Stocks In Focus: 

Saying the stock value is now "compelling" and the "worst appears over," Brean Murray gives the first upgrade on Abercrombie & Fitch Co. (ANF, $51.82, +$2.21, +4.45%) by the Street in months. It moves the teen-apparel retailer to buy while setting a $65 price target and boosts earnings-per-share targets for the next two years. Among other reasons to be bullish, Brean Murray notes, "After entering 1Q with materially too much inventory, we believe a warmer March has allowed the company to become more right-sized in terms of product exposure and should position [ANF] to be more strategic going forward."

JPMorgan upgraded Alliant Techsystems Inc. (ATK, $52.55, +$2.43, +4.85%) to overweight, saying the defense contractor's reduced earnings outlook is more than fully priced into the stock. Last month, Alliant predicted fiscal 2013 results would fall short of Wall Street expectations due to near-term growth challenges. Its stock had dropped steeply since then.

Amazon.com Inc. (AMZN, $198.95, -$3.56, -1.76%) slid on Bank of America Merrill Lynch's downgrade of the ecommerce giant to neutral. After an 18% rise in 1Q, the ratings cut comes as the investment bank believes consensus estimates on Amazon are too high, starting with this quarter, while "increasing competitive pressures in digital media" from Apple (AAPL, $615.24, +$15.69, +2.62%) and Google (GOOG, $645.12, +$3.88, +0.61%) should keep AMZN's "valuation multiple in check." Bank of America is keeping its price target at $235.

Apollo Investment Corp. (AINV, $7.49, +$0.32, +4.46%) said Apollo Global Management LLC (APO, $14.30, +$0.02, +0.14%) purchased about $50 million, or about 5.9 million shares, of newly issued Apollo Investment stock amid plans to expand its focus. Apollo Investment also said it is beginning a search for a new chief financial officer after its earlier choice was unable to join the company due to a scheduling conflict.

AVI BioPharma Inc. (AVII, $1.10, -$0.44, -28.64%) said a 24-week study showed that eteplirsen had a statistically significant effect in raising the level of a key protein, dystrophin, in boys with Duchenne muscular dystrophy. But patients given the drug for only 12 weeks showed no significant increase in dystrophin, despite the administration of the drug at a higher dose, suggesting that a longer duration of treatment is required.

Bank of the Ozarks Inc.'s (OZRK, $31.92, +$0.66, +2.11%) board approved a penny increase in its quarterly dividend, allowing the regional bank to raise its payout for the seventh straight quarter. The bank said Monday it will now pay shareholders 12 cents a share, a 9.1% increase over its prior payout, which will cost an additional $345,500 a quarter.

Raymond James downgraded its stock-investment rating on Buffalo Wild Wings Inc. (BWLD, $88.19, -$2.50, -2.76%) to underperform from market perform, citing the combination of record valuation metrics for the stock, a current chicken-wing shortage that could be of long duration and the beginning of a softer seasonal demand period for sports bars.

JPMorgan cut its stock-investment rating on Exelis Inc. (XLS, $12.13, -$0.40, -3.15%) to neutral after the recent run-up in the stock. Shares of the aerospace and defense stock are up about 34% year-to-date, fueled by pension optics.

After Friday's 16% slump, shares of Finish Line Inc. (FINL, $20.63, -$0.60, -2.80%) are sliding further as analysts continue to weigh in on the retailer's dour per-share earnings news and planned hike in tech spending.

Kohl's Corp. (KSS, $51.48, +$1.45, +2.90%) has missed the rally that other retail stocks have enjoyed this year, but the tide may be ready to turn, says J.P. Morgan at it upgrades the department-store chain to neutral and raised its price target to $55 from $42. The investment bank cites three near-term potential catalysts--Kohl's is seeing more people signing up for its credit cards, a group that tends to spend more; inventory is becoming more balanced with anticipated demand; and recent and new product launches.

After surging 60% since mid-December on turnaround hopes and signs of an improved housing market, Lumber Liquidators (LL, $24.47, -$0.64, -2.55%) moves back from last week's nine-month high as Stifel Nicolaus downgrades the closeout flooring seller to hold in a valuation call. Though the firm said it is bullish over the next five years for a material recovery in consumer-remodeling activity, it said it is concerned that investors have gotten overly excited near-term as flooring sales in the first quarter, while better, are only marginally so.

Bank holding company National Penn Bancshares Inc. (NPBC, $9.21, +$0.36, +4.08%) raised its dividend by 40% to 7 cents a share and unveiled a plan to buy back up to 7.5 million shares of its stock, joining a growing list of firms looking to bolster shareholder value.

Fortis Healthcare, a provider of integrated health-care services in India, and Masimo Corp. (MASI, $24.10, +$0.72, +3.08%) said they reached a multiyear medical-technology supplier agreement that allows Fortis hospitals access to Masimo's full line of pulse oximetry and noninvasive, continuous patient-monitoring services.

After already climbing nearly 40% since late November, Piper Jaffray gives up the bear case on PetMed Express Inc. (PETS, $12.99, +$0.61, +4.93%) and upgrades its stock-investment rating on the company to neutral while raising its price target 20% to $12 and boosting estimates for this year and next. It contends downside risk at current levels is limited, citing among other factors the outlook for the online pet-medicine company isn't "as dire as previously expected heading into seasonally strong part of the year."

Regional carrier Pinnacle Airlines Corp. (PNCL, $0.58, -$0.77, -56.78%) filed for bankruptcy as the company seeks to restructure its agreements with Delta Air Lines Inc. (DAL, $10.02, +$0.10, +1.01%) and cut ties with United Airlines and US Airways Group Inc. (LCC, $7.52, -$0.07, -0.96%). The Memphis, Tenn., carrier filed for Chapter 11 protection Sunday with $1.4 billion worth of debt and $1.5 billion worth of assets, according to papers it filed in U.S. Bankruptcy Court in Manhattan.

Nutritional-supplements company Schiff Nutrition International Inc. (WNI, $13.16, +$0.87, +7.08%) acquired Airborne Inc. for $150 million in cash, giving it control of the well-known maker of cold-fighting tablets and allowing it to expand its position in the immune-support market. Schiff acquired Airborne from the private-equity arm of GF Capital Management & Advisors LLC.

It's time to take a breather on shares of Texas Instruments (TXN, $33.20, -$0.41, -1.22%) and Linear Tech (LLTC, $33.15, -$0.55, -1.63%), UBS says. The firm cuts its stock-investment ratings on both companies to neutral from buy, saying valuation and estimates are ahead of fundamentals. UBS is positive on the chip sector, but says industrial recovery isn't fast enough as weakness in China offsets strength in US. In addition, the wireless infrastructure market remains weak.

GlaxoSmithKline PLC (GSK.LN) Monday underscored how important the experimental drug Relovair is for its future by lifting its stake in the lung treatment's U.S.-developer Theravance Inc. (THRX, $22.73, +$3.23, +16.56%) to 26.8% from just under 19%, at a cost of just under $213 million. Glaxo, Britain's biggest drug maker, is paying $21.2887 a share for 10 million Theravance shares, a 7.5% premium to the five-day average price up to March 30.

Wireless-broadband-network services-provider Towerstream Corp. (TWER, $5.22, +$0.47, +9.89%) signed a Wi-Fi agreement with a national wireless carrier utilizing its current and future rooftop assets, the company said in a filing with the Securities and Exchange Commission late Friday.

Caris & Co. cut its stock-investment rating on Volterra (VLTR, $33.75, -$0.67, -1.93%) to average from above average, citing the stock's recent 55% jump since late November. The firm notes positive estimate revisions are already partially baked into shares as a result of strong March PC order data points.

-Edited by Corrie Driebusch and Ben Fox Rubin; write to corrie.driebusch@dowjones.com

Article from The Wall Street Journal